Contact
searchSearch
HMP Global
Login

Head & Neck Squamous Cell Carcinoma

Head & Neck Squamous Cell Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Benjamin Kann, MD
Videos
AI-Predicted Extranodal Extension Improves Risk Stratification in Oropharyngeal Carcinoma
01/14/2026
Benjamin Kann, MD
Benjamin Kann, MD, discusses results from a large retrospective study evaluating an automated AI-based imaging platform to predict extranodal extension in patients with oropharyngeal carcinoma using pretreatment CT scans.
Benjamin Kann, MD, discusses results from a large retrospective study evaluating an automated AI-based imaging platform to predict extranodal extension in patients with oropharyngeal carcinoma using pretreatment CT scans.
Benjamin Kann, MD, discusses...
01/14/2026
Oncology
Emma Connolly, MB BCh BAO
Videos
Redefining “High Risk” for Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck
10/21/2025
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO,...
10/21/2025
Oncology
Danny Rischin, MD, Peter MacCallum Cancer Centre
Videos
Adjuvant Cemiplimab as New Standard of Care for Patients With High-Risk Cutaneous Squamous Cell Carcinoma
06/06/2025
Danny Rischin, MD
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the...
06/06/2025
Oncology
Jean-Pascal Machiels, MD, Cliniques Universitaires Saint Luc
Videos
Pembrolizumab Added to Chemoradiotherapy May Improve EFS in Head and Neck Squamous Cell Carcinoma
11/15/2022
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Jean-Pascal Machiels, MD,...
11/15/2022
Oncology
Denis Soulières, Centre Hospitalier de l’Université de Montréal
Videos
Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
09/12/2022
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
Denis Soulières, MD, discusses...
09/12/2022
Oncology
Prof Vijay Maruti Patil, MBBS, MD, DM, Tata Memorial Centre, Mumbai, India
Videos
Docetaxel Added to Radiation Improves Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma
08/11/2022
Prof Vijay Maruti Patil, MBBS, MD, DM, discusses findings from a phase 3 trial that explored the use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
Prof Vijay Maruti Patil, MBBS, MD, DM, discusses findings from a phase 3 trial that explored the use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
Prof Vijay Maruti Patil, MBBS,...
08/11/2022
Oncology

Recent News

News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
Conference Coverage
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
News
Eflornithine Plus Lomustine vs Lomustine Monotherapy for Recurrent Grade 3 Astrocytoma: Phase 3 STELLAR Trial
01/13/2026
Gina Tomaine
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine...
01/13/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use